GlassScriptPhysician profile
Lawrence Lauridsen
NPI 1386993400
$3,783.17
in general payments reported to CMS, 2019-2025
28 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $284 · 2021: $464 · 2022: $617 · 2023: $638 · 2024: $689 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.26 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $336.46 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $303.81 | 2019-2025 | Verquvo, Capvaxive, Januvia |
| Amgen INC. | $280.80 | 2019-2025 | Evenity, Repatha, Prolia |
| Otsuka America Pharmaceutical, INC. | $262.23 | 2022-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $253.83 | 2019-2025 | |
| Lundbeck LLC | $227.26 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $205.48 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $204.97 | 2022-2024 | Azstarys, Azstarys |
| Glaxosmithkline, LLC. | $165.03 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $138.40 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $96.91 | 2019 | |
| Ironshore Pharmaceuticals INC. | $67.66 | 2024 | |
| Dexcom, INC. | $65.92 | 2022-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $63.81 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.21 | 2019-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.44 | 2025 | Caplyta |
| Viatris Specialty LLC | $53.04 | 2025 | Yupelri |
| Amarin Pharma, INC. | $50.18 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $48.27 | 2022 | |
| Xeris Pharmaceuticals, INC. | $39.96 | 2022-2023 | Gvoke Hypopen |
| Mylan Specialty L.P. | $28.48 | 2024 | Yupelri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.18 | 2023 | Aplenzin |
| Collegium Pharmaceutical, INC. | $20.35 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $19.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2024 | Eliquis |
| Exact Sciences Corporation | $14.83 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Lauridsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.